Literature DB >> 8969456

Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro.

U Schlokat1, B E Fischer, S Herlitschka, G Antoine, A Preininger, G Mohr, M Himmelspach, O Kistner, F G Falkner, F Dorner.   

Abstract

Recombinant human von Willebrand Factor (rvWF), a multimeric glycoprotein essential to haemostasis, has been developed as a potential therapeutic agent for treatment of von Willebrand disease (vWD). Permanent Chinese-hamster ovary (CHO)-rvWF cell clones co-expressing recombinant furin (rfurin) were established in order to ensure complete rvWF propeptide removal [Fischer, Schlokat, Mitterer, Reiter, Mundt, Turecek, Schwarz and Dorner (1995) FEBS Lett. 375, 259-262]. Large quantities of material are required for in vivo tests and clinical studies. This demand is commonly met by achieving high-yield expression of the desired protein via amplification. Co-amplification of rfurin, necessary to completely process increasing amounts of rvWF precursor, could not be accomplished, presumably due to lethal effects of overexpressed rfurin for the host cells [Creemers (1994) Ph.D. Thesis, University of Leuven]. Recent reports have inferred that rfurin can only mediate rvWF processing intracellularly [Rehemtulla and Kaufman (1992) Blood 79, 2349-2355; Rehemtulla, Dorner and Kaufman (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 8235-8239]. We report here that rvWF-precursor processing, however, occurs predominantly extracellularly upon rfurin co-expression. Mixing experiments employing rfurin- as well as rvWF-precursor-containing conditioned media demonstrate that rvWF precursors are accessible and cleavable by rfurin in vitro. Exposure to rfurin in vitro converts the heterogeneous multimer pattern typical of incompletely processed rvWF multimers into highly homogeneous and structurally intact multimers superior to the ones exhibited by plasma-derived vWF. These findings thus demonstrate the feasibility of large-scale production of a completely processed, intact and homogeneous rvWF preparation, based on individual rvWF-precursor high-yield expression and subsequent propeptide removal by rfurin in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969456

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  4 in total

1.  'Shed' furin: mapping of the cleavage determinants and identification of its C-terminus.

Authors:  B Plaimauer; G Mohr; W Wernhart; M Himmelspach; F Dorner; U Schlokat
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

2.  Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Authors:  A Preininger; U Schlokat; G Mohr; M Himmelspach; V Stichler; A Kyd-Rebenburg; B Plaimauer; P L Turecek; H P Schwarz; W Wernhart; B E Fischer; F Dorner
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

Review 3.  A multicenter consensus: A role of furin in the endothelial tropism in obese patients with COVID-19 infection.

Authors:  Antoine Fakhry AbdelMassih; Jianping Ye; Aya Kamel; Fady Mishriky; Habiba-Allah Ismail; Heba Amin Ragab; Layla El Qadi; Lauris Malak; Mariam Abdu; Miral El-Husseiny; Mirette Ashraf; Nada Hafez; Nada AlShehry; Nadine El-Husseiny; Nora AbdelRaouf; Noura Shebl; Nouran Hafez; Nourhan Youssef; Peter Afdal; Rafeef Hozaien; Rahma Menshawey; Rana Saeed; Raghda Fouda
Journal:  Obes Med       Date:  2020-07-15

Review 4.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.